Supernus's Bold Merger with Indivior Forges New CNS Powerhouse

ROCKVILLE, MD – August 03, 2026 – In a move that signals a major realignment in the biopharmaceutical landscape, Supernus Pharmaceuticals today announced a definitive agreement to merge with Indivior Pharmaceuticals. The announcement came alongside a stellar second-quarter earnings report that saw the company beat revenue expectations and raise its full-year guidance, providing a position of strength from which to execute this transformative deal. The all-stock "merger of equals" is set to create a diversified Central Nervous System (CNS) leader with significant scale, a complementary portfolio, and a bolstered pipeline, poised to reshape competition in both neurology and addiction medicine.

A Strategic Merger of Equals

The transaction is more than a simple acquisition; it's a strategic fusion designed to create a new entity greater than the sum of its parts. The combined company, to be named Supernus, Inc. and led by current Supernus CEO Jack Khattar, will merge Supernus’s broad portfolio in neurology and psychiatry with Indivior’s market-leading franchise in treatments for Opioid Use Disorder (OUD).

Under the terms of the all-stock agreement, Indivior shareholders will own approximately 56.5% of the new company, with Supernus shareholders holding the remaining 43.5%. The deal structure underscores the collaborative nature of the merger, aiming to leverage the distinct strengths of both organizations. The combined entity is projected to realize $125 million in annual cost synergies, creating financial flexibility to invest in growth and innovation.

“We are excited about the future of Supernus, even more so following the recent agreement to merge with Indivior Pharmaceuticals, Inc.,” said Jack Khattar, President and CEO of Supernus, in the company's announcement. “The combination of these two businesses will form a well-positioned CNS company with a unique profile of scale, growth, and flexibility to pursue additional business development opportunities.”

This strategic rationale is clear: in an increasingly competitive pharmaceutical market, scale matters. The merger provides not just a larger revenue base but also a more diversified one, reducing dependence on any single product or therapeutic area. By combining Supernus's commercial infrastructure in neurology with Indivior's specialized focus on addiction, the new company will be able to address a wider spectrum of complex brain diseases.

Growth as the Foundation for Transformation

Supernus enters this merger from a position of considerable financial and commercial momentum. The company reported total Q2 2026 revenues of $219.1 million, a robust 32% increase over the same period last year. This performance was driven by the company’s designated growth products—Qelbree®, GOCOVRI®, ZURZUVAE®, and ONAPGO™—which collectively saw revenues climb an impressive 52% to $175.7 million.

Qelbree, a treatment for ADHD, continues to be a major growth engine, with sales increasing 15% to $89.2 million, fueled by a 25% surge in prescriptions for the adult population. Collaboration revenue from the postpartum depression treatment ZURZUVAE, shared with Biogen, contributed a significant $35.4 million. Even the recently launched ONAPGO for Parkinson's disease is showing early promise, with $13.5 million in net sales and a steady increase in prescriber adoption.

This strong top-line performance, however, was juxtaposed with a reported GAAP operating loss of $58.0 million for the quarter. A closer look reveals this loss was almost entirely driven by a one-time, non-cash intangible asset impairment charge of $54.9 million related to APOKYN®, another Parkinson's treatment. When adjusting for this and other non-cash items, the company’s adjusted operating earnings stood at a healthy $31.2 million, painting a picture of strong underlying operational health. This financial strength gave the company the confidence to raise its full-year 2026 revenue guidance to a range of $860 million to $890 million, signaling sustained momentum for the remainder of the year.

A Complementary Portfolio for a Complex Market

The true strategic genius of this merger lies in the complementary nature of the two companies' portfolios. Supernus has meticulously built a diverse neuroscience platform spanning ADHD, Parkinson's disease, epilepsy, and depression. Indivior, on the other hand, is the undisputed leader in long-acting injectable treatments for OUD, with its flagship product, Sublocade, commanding an estimated 76% of the U.S. long-acting buprenorphine market.

By bringing these portfolios under one roof, the new Supernus, Inc. will address a wide continuum of CNS disorders. The synergy is not just in the science but also in the commercial approach. The combined entity can leverage a broader and more specialized sales force to engage with healthcare providers across neurology, psychiatry, and addiction treatment centers. This creates opportunities for enhanced market penetration and cross-promotional activities that neither company could achieve alone.

Indivior’s own recent performance highlights the value it brings to the merger. The company also reported a stellar quarter, with Sublocade revenues surging 21% year-over-year to a record $253 million. This powerful, high-growth asset provides a strong counterbalance to Supernus’s more traditional CNS products, some of which face generic competition. This diversification de-risks the combined company’s revenue stream and establishes a powerful platform for durable, long-term growth.

Charting the Path Forward

The market has already rendered a positive verdict on the transaction, with shares of both Supernus and Indivior surging in pre-market trading following the announcement. Investors clearly recognize the industrial logic of creating a scaled and diversified CNS leader. The combined pipeline, which includes promising candidates for treatment-resistant depression and substance use disorders, now has the financial backing of a larger, more profitable enterprise.

The anticipated $125 million in annual synergies is not just a line item for investors; it represents freed-up capital that can be redeployed into the R&D engine to accelerate the development of novel therapies. With the merger expected to close in the fourth quarter of 2026, the integration process will be critical. However, with a clear strategic vision and strong leadership under Jack Khattar, the new Supernus, Inc. is well-positioned to execute on its promise.

This merger is more than a financial transaction; it's a structural shift in the CNS market. By combining expertise in neurology, psychiatry, and addiction, the newly formed company is creating an integrated platform to tackle some of the most challenging and prevalent brain disorders facing society today.